Seventy-one IBD patients with active disease, 85 consecutive IBD patients initiating ustekinumab therapy, 25 patients initiating anti-TNF therapy and 32 patients initiating vedolizumab therapy were prospectively recruited. The gene discussed is TNF; the disease is inflammatory bowel disease.